Key Points
- Director Dennis Matheis bought 245,000 Lucid Diagnostics shares at $1.00 each, spending $245,000 and boosting his direct ownership to about 1.03 million shares.
- Lucid Diagnostics recently reported weaker-than-expected quarterly results, posting a loss of $0.07 per share on revenue of $1.26 million, both below analyst estimates.
- Wall Street remains mixed but mostly positive on the stock, with a Moderate Buy consensus and an average price target of $4.13, while institutional ownership stands at 74.01%.
Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) Director Dennis Matheis purchased 245,000 shares of the stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $1.00 per share, with a total value of $245,000.00. Following the transaction, the director directly owned 1,033,443 shares in the company, valued at approximately $1,033,443. This trade represents a 31.07% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
Lucid Diagnostics Price Performance
NASDAQ LUCD opened at $1.00 on Friday. The firm has a market cap of $203.07 million, a PE ratio of -2.13 and a beta of 1.10. The company has a 50 day moving average price of $1.16 and a 200 day moving average price of $1.18. Lucid Diagnostics Inc. has a 52 week low of $0.90 and a 52 week high of $1.70.
Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $1.26 million for the quarter, compared to analysts' expectations of $1.38 million. On average, equities research analysts anticipate that Lucid Diagnostics Inc. will post -0.22 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts have issued reports on LUCD shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Lucid Diagnostics in a report on Wednesday, May 6th. Needham & Company LLC reaffirmed a "buy" rating and issued a $3.00 price target on shares of Lucid Diagnostics in a report on Thursday, March 26th. Ascendiant Capital Markets raised their price target on shares of Lucid Diagnostics from $8.25 to $9.00 and gave the stock a "buy" rating in a report on Thursday, April 9th. Maxim Group decreased their price target on shares of Lucid Diagnostics from $3.00 to $2.00 and set a "buy" rating for the company in a report on Friday, May 15th. Finally, BTIG Research reiterated a "buy" rating and issued a $2.50 price objective on shares of Lucid Diagnostics in a research note on Friday, May 15th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Lucid Diagnostics currently has a consensus rating of "Moderate Buy" and an average target price of $4.13.
View Our Latest Stock Analysis on LUCD
Institutional Investors Weigh In On Lucid Diagnostics
A number of hedge funds have recently modified their holdings of the business. Bank of America Corp DE raised its position in shares of Lucid Diagnostics by 25.9% in the first quarter. Bank of America Corp DE now owns 88,527 shares of the company's stock valued at $102,000 after buying an additional 18,212 shares during the last quarter. Sunbelt Securities Inc. raised its position in shares of Lucid Diagnostics by 134.4% in the first quarter. Sunbelt Securities Inc. now owns 900,013 shares of the company's stock valued at $1,035,000 after buying an additional 516,014 shares during the last quarter. XML Financial LLC raised its position in shares of Lucid Diagnostics by 24.8% in the first quarter. XML Financial LLC now owns 223,195 shares of the company's stock valued at $257,000 after buying an additional 44,400 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Lucid Diagnostics in the fourth quarter valued at about $246,000. Finally, Millennium Management LLC acquired a new stake in shares of Lucid Diagnostics in the fourth quarter valued at about $168,000. 74.01% of the stock is currently owned by institutional investors and hedge funds.
Lucid Diagnostics Company Profile
(
Get Free Report)
Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company's flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid's CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.
Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
